Cargando…

Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients

Daprodustat is a hypoxia‐inducible factor‐prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. This phase 3 study evaluated the efficacy and safety of daprodustat in an uncontrolled cohort of 56 Japanese peritoneal dialysis patients with anemia over 52 weeks. Subjects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanai, Hidetoshi, Nangaku, Masaomi, Nagai, Reiko, Okuda, Nobuhiko, Kurata, Kyo, Nagakubo, Takashi, Endo, Yukihiro, Cobitz, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290017/ https://www.ncbi.nlm.nih.gov/pubmed/33964183 http://dx.doi.org/10.1111/1744-9987.13686

Ejemplares similares

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure
por: Caltabiano, Stephen, et al.
Publicado: (2019)

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
por: Ishii, Taisuke, et al.
Publicado: (2021)

Extraperitoneal Placement of a Peritoneal Dialysis Catheter
por: Nakamura, Yasuna, et al.
Publicado: (2018)

An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function
por: Mahar, Kelly M., et al.
Publicado: (2022)

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial
por: Singh, Ajay K., et al.
Publicado: (2022)

Peritoneal Dialysis-Related Peritonitis Caused by Streptococcus oralis
por: Kotani, Akihiro, et al.
Publicado: (2021)

The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects
por: Caltabiano, Stephen, et al.
Publicado: (2018)

Daprodustat: First Approval
por: Dhillon, Sohita
Publicado: (2020)

A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis
por: Bailey, Christine K., et al.
Publicado: (2019)

Increased peritoneal permeability at peritoneal dialysis initiation is a potential cardiovascular risk in patients using biocompatible peritoneal dialysis solution
por: Hamasaki, Yoshifumi, et al.
Publicado: (2014)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
por: Meadowcroft, Amy M, et al.
Publicado: (2018)

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
por: Tsuruya, Kazuhiko, et al.
Publicado: (2019)

Time until treatment initiation is associated with catheter survival in peritoneal dialysis-related peritonitis
por: Oki, Rikako, et al.
Publicado: (2021)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease
por: Holdstock, Louis, et al.
Publicado: (2018)

Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination
por: Mahar, Kelly M., et al.
Publicado: (2021)

Prognostic significance of concentric left ventricular hypertrophy at peritoneal dialysis initiation
por: Tomura, Misato, et al.
Publicado: (2021)

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
por: Ito, Sadayoshi, et al.
Publicado: (2021)

Hospitalization for Patients on Combination Therapy With Peritoneal Dialysis and Hemodialysis Compared With Hemodialysis
por: Tanaka, Mototsugu, et al.
Publicado: (2020)

Catheter Diversion Procedure With Exit-Site Renewal Promotes Peritoneal Dialysis Catheter Survival
por: Oki, Rikako, et al.
Publicado: (2020)

A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity
por: Nakayama, Masaaki, et al.
Publicado: (2020)

Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2020)

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis
por: Fadlalmola, Hammad, et al.
Publicado: (2022)

Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study
por: Usui, Tomoko, et al.
Publicado: (2020)

Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study
por: Iso, Takashi, et al.
Publicado: (2022)

Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
por: Zheng, Qiyan, et al.
Publicado: (2021)

Safety of Endoscopy in Peritoneal Dialysis Patients
por: Kim, Joon Sung, et al.
Publicado: (2021)

The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry
por: Maruyama, Yukio, et al.
Publicado: (2015)

Daprodustat: A potential game-changer in renal anemia therapy—A perspective
por: Haider, Muhammad Usman, et al.
Publicado: (2023)

A new peritoneal dialysis fluid for Japanese patients: a randomized non-inferiority clinical trial of safety and efficacy
por: Nakayama, Masaaki, et al.
Publicado: (2016)

An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat
por: Becker, Kimberly A., et al.
Publicado: (2017)

Daprodustat Accelerates High Phosphate-Induced Calcification Through the Activation of HIF-1 Signaling
por: Tóth, Andrea, et al.
Publicado: (2022)

Prevalence of Zinc Deficiency in Japanese Patients on Peritoneal Dialysis: Comparative Study in Patients on Hemodialysis
por: Shimizu, Satoshi, et al.
Publicado: (2020)

Development of a risk prediction model for infection-related mortality in patients undergoing peritoneal dialysis
por: Tsujikawa, Hiroaki, et al.
Publicado: (2019)

Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies
por: Akizawa, Tadao, et al.
Publicado: (2021)

The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients
por: Ye, Hongjian, et al.
Publicado: (2017)

A Single‐Dose, Open‐Label, Randomized, Two‐Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat
por: Yamada, Masanori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4qo3djr5mdfohn5l99egarmk9e